论文部分内容阅读
目的分析肺心病合并呼吸衰竭患者治疗中低分子肝素钙应用效果。方法选取医院收治的肺心病合并呼吸衰竭患者106例,按照随机划分方法分为对照组与观察组各53例,对照组给予对症治疗方法,观察组对症治疗同时引入低分子肝素钙治疗,观察比较两组患者治疗效果,同时比较治疗前后两组患者动脉血气指标情况。结果治疗效果比较,观察组96.23%(51/53)高于对照组79.25%(42/53),两组患者比较差异有统计学意义(P<0.05)。治疗前两组患者PaO_2与PaCO_2差异无统计学意义(P>0.05),治疗后观察组改善情况明显优于对照组,两组患者比较差异有统计学意义(P<0.05)。结论肺心病合并呼吸衰竭患者治疗中,低分子肝素钙应用下可取得显著治疗效果,应在临床实践中推广应用。
Objective To analyze the therapeutic effect of low molecular weight heparin in patients with pulmonary heart disease and respiratory failure. Methods 106 patients with pulmonary heart disease complicated with respiratory failure admitted to hospital were divided into control group and observation group according to randomization method. Each group was given symptomatic treatment. The observation group received symptomatic treatment with low molecular weight heparin treatment. Two groups of patients with treatment, at the same time, before and after treatment in both groups of patients with arterial blood gas index. Results Compared with the control group, 96.23% (51/53) in the observation group was significantly higher than 79.25% (42/53) in the control group, with significant difference between the two groups (P <0.05). There was no significant difference between PaO2 and PaCO2 in the two groups before treatment (P> 0.05). After treatment, the improvement in observation group was better than that in control group. The difference between the two groups was statistically significant (P <0.05). Conclusion In the treatment of patients with pulmonary heart disease complicated with respiratory failure, low molecular weight heparin can achieve significant therapeutic effect and should be popularized and applied in clinical practice.